Back to discover
Drug

Sevoflurane

Established medicine
ClassGABA-A receptor; anion channel positive allosteric modulatorResearchOngoing clinical research
Also known as Petrem, SevoFlo, Sevospire, Sojourn+7 more

Petrem, SevoFlo, Sevospire, Sojourn, Ultane, Sevofluran, Sevoflurano, Sévoflurane, 1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane, Fluoromethyl 2,2,2-trifluoro-1-(trifluromethyl)ethyl ether, Sevofluranum.

1
Research papers
17
Active clinical trials
23
Protein targets
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Dynamic Effects of Different Anesthetic Agents on the Immune Function of Healthy Volunteers

Clinical trial2026-08-31Primary completion · ClinicalTrials.gov

Response Surface Model Between Remimazolam and Sevoflurane; Comparison of the Minto and the Greco Model

Clinical trial2026-06-02Results expected Q2 2027 · ClinicalTrials.gov

Effect of Sevoflurane on Sweat Threshold in Children of Different Ages

Clinical trial2026-05-01Primary completion · ClinicalTrials.gov

Sevoflurane's Effect on Neurocognition Study

Clinical trial2026-01-30Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Sevoflurane
Aliases & brands
PetremSevoFloSevospireSojournUltaneSevofluranSevofluranoSévoflurane1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propaneFluoromethyl 2,2,2-trifluoro-1-(trifluromethyl)ethyl etherSevofluranum
RxNorm CUI
36453
ChEMBL ID
CHEMBL1200694
ATC codes
N01AB08
UNII
38LVP0K73A
Primary mechanism
GABA-A receptor; anion channel positive allosteric modulator

Pharmacology & targets

23 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE MODULATORGlycine receptor (alpha-1/beta) positive modulator
POSITIVE MODULATORGlycine receptor (alpha-1/beta) positive modulator
OPENERPotassium channel subfamily K member 10 opener
OPENERPotassium channel subfamily K member 18 opener
OPENERPotassium channel subfamily K member 3 opener
OPENERPotassium channel subfamily K member 9 opener
OPENERPotassium channel subfamily K member 2 opener

Clinical trials

198 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
198
registered trials across all phases
LATEST COMPLETION 2026
17
Active studies
13
Recruiting
176
Late-stage (III+)
120
Completed
61
Discontinued
PHASE DISTRIBUTIONn = 198
Early Phase 13Phase 17Phase 1 / 23Phase 29Phase 2 / 33Phase 319Phase 470Phase N / A84

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes5
Acyltransferases1Myelin Sheath1Oligodendroglia1Receptors, Transferrin1Sevoflurane1
Journals, researchers & institutions
Top journals
  • Journal of advanced research1
Leading researchers
  • Cao Q1
  • Chen Y1
  • Dong H1
  • Jia S1
  • Liu H1
  • Liu Y1
  • Ou Z1
  • Su B1
Leading institutions
free-text, unnormalised
  • Binzhou Medical University Hospital1
  • Histology and Embryology & K.K. Leung Brain Research Centre1
  • State Key Laboratory of Cellular Stress Biology1
  • Xijing Hospital1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials